Abbott Laboratories (ABT) Covered Calls

Abbott Laboratories covered calls Abbott Laboratories is a global healthcare leader that develops, manufactures, and sells a broad line of products across medical devices, diagnostics, nutrition, and generic pharmaceuticals. By 2026, the company has solidified its dominance in cancer diagnostics through the acquisition of Exact Sciences. Abbott is renowned for its market-leading FreeStyle Libre glucose monitors, structural heart technologies, and a robust portfolio of established medicines serving emerging markets.

You can sell covered calls on Abbott Laboratories to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ABT (prices last updated Thu 4:16 PM ET):

Abbott Laboratories (ABT) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
111.47 -2.12 111.52 112.41 11.4M 14 198
Covered Calls For Abbott Laboratories (ABT)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 111 1.71 110.70 0.3% 12.2%
Mar 20 110 4.45 107.96 1.9% 18.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Core Business and Products

Abbott operates a resilient, diversified business model that minimizes reliance on any single healthcare sector. By 2026, the company has pivoted heavily toward precision diagnostics and chronic disease management. Their primary segments include:

  1. Medical Devices: The company's fastest-growing division, led by the FreeStyle Libre continuous glucose monitoring (CGM) system and advanced "structural heart" solutions like the TriClip and Aveir leadless pacemakers.
  2. Diagnostics: Enhanced by the 2026 acquisition of Exact Sciences, this segment now leads in cancer screening with the Cologuard and Oncotype DX platforms, alongside its Alinity core laboratory systems.
  3. Nutrition: A world leader in pediatric and adult nutrition, featuring brands like Similac and Ensure, which are undergoing a "strategic volume reset" in 2026 with eight new product launches.
  4. Established Pharmaceuticals (EPD): A portfolio of high-quality branded generic medicines specifically tailored for high-growth emerging markets in Asia, Latin America, and the Middle East.

Competitive Landscape

Abbott competes against specialized medical technology firms and diversified healthcare conglomerates. In the diabetes and heart health sectors, its most direct rivals are Medtronic and Dexcom. In the diagnostics space, it faces stiff competition from Danaher and Thermo Fisher Scientific. Within the nutrition and pharmaceutical markets, it encounters global giants such as Nestlé and Pfizer. Despite these rivals, Abbott’s "cradle-to-grave" healthcare ecosystem and its status as a Dividend King provide a competitive moat that is difficult to replicate.

Strategic Outlook and Innovation

Abbott’s 2026 strategy is defined by "The Great Diagnostic Pivot," shifting from pandemic-era testing to oncology and early cancer detection via the Exact Sciences integration. A major focal point is AI-Driven Bio-Wearables, with the rollout of the Lingo consumer biowearable and a new dual-analyte sensor that tracks both glucose and ketones. In the surgical space, Abbott is advancing Pulsed Field Ablation (PFA) via the Volt system to treat atrial fibrillation with greater precision. Management has issued a bullish 2026 outlook, targeting 7% organic sales growth as the Nutrition segment recovers and new Medical Device approvals reach full commercial scale. By maintaining a disciplined R&D pipeline and leveraging its vast global distribution network, Abbott aims to remain the primary orchestrator of data-driven, personalized healthcare delivery.